A. Katsanos Et Al. , "A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension," EXPERT OPINION ON DRUG SAFETY , vol.21, no.4, pp.525-539, 2022
Katsanos, A. Et Al. 2022. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. EXPERT OPINION ON DRUG SAFETY , vol.21, no.4 , 525-539.
Katsanos, A., Riva, I., BOZKURT, B., Hollo, G., Quaranta, L., Oddone, F., ... Irkec, M.(2022). A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. EXPERT OPINION ON DRUG SAFETY , vol.21, no.4, 525-539.
Katsanos, Andreas Et Al. "A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension," EXPERT OPINION ON DRUG SAFETY , vol.21, no.4, 525-539, 2022
Katsanos, Andreas Et Al. "A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension." EXPERT OPINION ON DRUG SAFETY , vol.21, no.4, pp.525-539, 2022
Katsanos, A. Et Al. (2022) . "A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension." EXPERT OPINION ON DRUG SAFETY , vol.21, no.4, pp.525-539.
@article{article, author={Andreas Katsanos Et Al. }, title={A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension}, journal={EXPERT OPINION ON DRUG SAFETY}, year=2022, pages={525-539} }